FDA Approves First Targeted Therapy to Treat Patients with Painful Complication of Sickle Cell Disease

On November 15, 2019, the U.S. Food and Drug Administration approved Adakveo (crizanlizumab-tmca), a treatment to reduce the frequency of vaso-occlusive crisis – a common and painful complication of sickle cell disease that occurs when blood circulation is obstructed by sickled red blood cells – for patients age 16 years and older.

“Hope has never been higher for people living with sickle cell disease and their families and supporters, with a pipeline of new treatments on the horizon, like the one being approved today, and several initiatives underway to better utilize current tools in the battle against the painful and deadly blood disorder,” said Acting FDA Commissioner Adm. Brett P. Giroir, M.D. “The opportunity before us in the coming months and years is profound and historic.”

Read more >>

Share this post

CONTACT US
KEEP IN TOUCH
Sign up for our email list, or follow us on social media, to stay in-the-know about the Maryland Sickle Cell Disease Association
Scroll to Top

New SCD Resource

Prince George's County

If you have sickle cell disease (SCD) and you live in Prince George's County (PGC), or if you know someone with SCD living in PGC, we have a SCD program specifically for PGC residents!